ClinicalTrials.gg
Not yet recruitingNCT06186544PROMOTEGLASSUpdated Jan 2, 2024

Validating GLASS Score in Predicting Acute Limb Events in CLTI Patients

An observational study in Chronic Limb-Threatening Ischemia, sponsored by Cardiff and Vale University Health Board. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-02.

Sponsored by Cardiff and Vale University Health Board · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · United Kingdom.

Planned enrollment
7th of 11
200 · median 250
Started
2024
with 2 others
Observational
11 of 23
6 open now
Registered
17th of 23
by date
Lead sponsor
1 of 23
Cardiff and Vale University Health Board

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 17th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, or all of them as a file.
02

Study summary

Ischemia is a severe medical condition that occurs when the blood and oxygen supply to a specific part of the body is significantly reduced or completely absent, it can affect any body part, often the legs. It is typically caused by the narrowing or blockage of an artery and can result in severe pain, tissue gangrene, and the potential loss of a limb (Amputation). This condition requires medical intervention and will not improve on its own.

To diagnose leg ischemia, the doctor will conduct a thorough vascular clinical examination. Depending on the findings, further imaging tests such as duplex ultrasound, magnetic resonance arteriography (MRA), or computed tomography (CT) may be conducted. In some cases, an arteriogram may be necessary which is an x-ray of the arteries while the dye is injected into the blood vessels.

Following the diagnosis, the best management course is recommended by a multidisciplinary team (MDT), considering each patient's disease pattern and overall health. Treatment options include performing a key-hole procedure, called an endovascular procedure (EVT) within the artery, where the vascular surgeon will be using a balloon to widen the artery, and/or a wire-reinforced stent which remains inside the artery serving as a scaffolding to keep it open.

The primary aim of the PROMOTE GLASS study is to investigate if the Global Anatomical Staging System (GLASS) score, which is a summation of points given according to the disease pattern as seen on assessment images (Duplex Ultrasound, MRA, and CT scans) can accurately tell if the treatment using catheters and stents inside blood vessels will work well for people with ischemia in their legs. The researchers also want to see if the GLASS score can predict how well patients with ischemia will heal and if they will need further treatments in the long term after having treatment with catheters and stents inside their blood vessels.

A prospective, observational study will be delivered by Cardiff and Vale University Health Board (CAVUHB). The vascular team will prospectively collect data over a 12-month period. This will be in patients undergoing elective and/or emergency primary EVT procedure, with follow-up 4-6 weeks after the procedure and at 12 months.

Read the detailed description

The Global Vascular Guideline (GVG) is an expert consensus, representing every major vascular society, aiming to promote a standardized evidence-based approach to assessing and treating patients with Chronic Limb Threatening Ischemia (CLTI). In terms of revascularization, the GVG recommendations revolve around three independent variables: patient risk, limb severity, and anatomic complexity (PLAN). Each section is fundamental to providing successful treatment to the patient, much controversy remains on which patterns of anatomical disease should be treated with endovascular or open surgery. To that end, the GLobal Anatomic Staging System (GLASS) was developed and adopted by the GVG committee as an angiographic scoring system to quantify the extent of infra-inguinal disease and predict the likely success of treatment with endovascular techniques (EVT).

GLASS is intended to predict the immediate technical success (ITS) and the 1-year limb base patency (LBP) after the EVT of the target artery pathway (TAP) and therefore aid in decision making. Currently there is no other risk prediction score or risk prediction model that estimates the probability of having ITS, LBP, major adverse limb events (MALE), major lower limb amputation (MLLA) and overall survival (OS) in patients presenting with CLTI who undergo EVT.

The purpose of this longitudinal prospective study is to examine the validity and reliability of the GLASS score in predicting ITS, LBP, MALE, MLLA, and OS in patients with CLTI, eventually helping to identify those patients who are likely to benefit from EVT. This could help clinicians make more informed decisions about treatment options, potentially reducing the need for more invasive procedures and improving patient outcomes. Additionally, the GLASS score could be used as a tool for patient selection in future clinical trials evaluating endovascular interventions for CLTI.

This study will follow a prospective observational study design. The study will initially be conducted within the Southeast Wales Vascular Network at Cardiff and Vale University Health Board. However, the study protocol allows for the inclusion of other hospitals or vascular units to participate in a collaborative model or as primary investigator sites, subject to obtaining necessary ethics approval and sponsorship agreement. The decision to involve additional sites will be made following a thorough evaluation by the research and development (R\&D) committee. This approach will ensure compliance with ethical guidelines and regulatory requirements while also fostering potential collaboration and broadening the study's reach and generalizability.

Patients will be identified through routine clinic referrals and emergency presentations with CLTI; only patients who are referred for EVT will be recruited. Recruited patients will consent to access to their medical files and radiological data (duplex scans and angiography images) and a clinical follow-up up to one year. Standard care pathways are followed beyond this point. Outcome data will be collected from patients' medical files and interventional radiology reports immediately after the EVT and from vascular surgery clinic follow-up notes over a 12 months period. Symptom scores, admissions records, clinical and imaging data will be analysed at the end of follow-up to validate risk prediction. This will be supported by the European Vascular Research Collaborative (EVRC).

This study will be supervised by the Chief Investigator, Mr. Lewis Meecham (Consultant Vascular and Endovascular Surgeon) and sponsored by Cardiff and Vale University Health Board. An internal management group consisting of clinicians, researchers and managerial staff will be established to oversee and monitor the progress of the study. The management group will meet on a monthly basis to raise, discuss, and resolve any issues arising during the conduct of the study.

03

Conditions studied

  • Chronic Limb-Threatening Ischemia

Keywords

  • CLTI
  • Chronic Limb Threatening Ischemia
  • Revascularization
  • MALE
  • MLLA
  • Limb based patency
  • Global Anatomical Staging system (GLASS)
  • Angioplasty
  • Lower limb bypass
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study participants will consist of adult vascular patients diagnosed with chronic limb threatening ischemia (CLTI) who are scheduled to undergo endovascular intervention according to the standard care pathway. These participants will be selected from vascular surgery MDT and will represent a diverse range of demographics and clinical characteristics. Participants will be included based on specific eligibility criteria, such as age, severity of CLTI, previous interventions in the limb of interest and willingness to participate in the study. Throughout the study, participants will be followed longitudinally, with their GLASS scores recorded at presentation and major acute limb events monitored over 12 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with peripheral vascular disease (PVD) under investigation for CLTI
  2. Age 18 years or older
  3. Able to consent to inclusion.

Exclusion criteria

Exclusion Criteria:

  1. Patient with traumatic or iatrogenic lesions leading to CLTI.
  2. Acute Limb Ischemia (symptoms for \<2 weeks)
  3. Patients who have undergone open/endovascular revascularization of the same limb within the last 12 months
  4. Patients who present with inflow disease (Common iliac artery (CIA), External Iliac Artery (EIA), and Common Femoral artery (CFA) disease) not intended for treatment during the same admission or prior to recruitment.
  5. Palliative revascularization (for pain in end of life)
  6. Patient with expected problems of maintaining a 1-year follow-up (e.g., no fixed address)
  7. Patients with previously implanted devices (stents) within the affected segment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Rate of Immediate Technical Success i.e. achievement of straight in-line flow to the foot as judged from the completion angiography

    Immediate technical success (ITS): The successful completion of endovascular therapy procedures without any major complications. Specifically, it is the successful achievement of the intended treatment goals, such as revascularization, stent deployment, or atherectomy. A procedure is considered to have achieved ITS when the desired therapeutic objectives are accomplished and the patient's vascular anatomy is adequately restored, without the need for additional intervention or conversion to open surgery.

    Time frame: Day 0

  2. Rate of The immediate technical failure (ITF)

    Immediate technical failure (ITF): ITF is defined as the inability to successfully perform the desired endovascular intervention due to technical limitations. It encompasses scenarios such as inadequate vessel access, equipment malfunction, or procedural complications that prevent the completion of the intended procedure.

    Time frame: Day 0

  3. Rate of LBP (as judged by the main surgeon based on symptoms and imaging up to 12 months)

    Limb based patency (LBP): limb-based patency (LBP) is defined as continued patency throughout the length of a defined target artery pathway (TAP) from the groin to the ankle. The TAP consists of the femoropopliteal (FP) segment, and a primary infrapopliteal (IP) runoff artery selected by the treating physician to achieve in-line flow to the foot or wound. LBP combines freedom from reintervention, occlusion, and severe stenosis of the TAP, along with freedom from hemodynamic failure (a significant decrease in ankle or toe pressures) in the presence of recurrent or unresolved CLTI symptoms.

    Time frame: Day 1 and up to 12 months

Secondary outcomes

  1. Rate of MALE (as judged by the main surgeon based on symptoms and imaging up to 12 months)

    Major adverse limb events (MALE): MALE is defined as limb-related events including major amputations, acute limb ischemia requiring urgent revascularization, or repeat interventions due to disease progression or complications.

    Time frame: Day 1 and up to 12 months

  2. Rate of MLLA (as judged by the main surgeon based on symptoms and imaging up to 12 months)

    Major Lower Limb Amputation (MLLA): MLLA is defined as above ankle amputations of the leg i.e. either above knee amputation (Transfemoral amputation), below knee amputation (Transtibial amputation), or through knee amputation.

    Time frame: Day 1 and up to 12 months

  3. Overall survival (in months)

    Overall survival (OS): OS is defined as freedom from death up to 12 months from the treatment date due to any cause.

    Time frame: Day 1 and up to 12 months

  4. Timings of any adverse clinical event (MALE, MLLA, Mortality)

    If presented before the scheduled follow up

    Time frame: Day 1 and up to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The study will take place in Cardiff and Vale UHB. All investigators and researchers must comply with the requirements of the General Data Protection Regulation (GDPR) Europe (EU) (2016/679) with regards to the collection, storage, processing, and disclosure of personal information. Data collected during the course of the study will be kept strictly confidential and accessed only by members of the study team. Data will be entered directly into the study database via a secure data capture and management software (CASTOR) that is GDPR compliant, access will be granted for the responsible surgeons only. Each case will be given a pseudo-anonymized number to avoid sharing of patient identifiable information. Study data will be archived in accordance with the Cardiff \& Vale UHB Archiving of Clinical Trial and Research Study Data Standard Operating Procedure. No personal identifiable data relating to patients will be retained beyond the end of the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jan 2026, 24 months later.

Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Jan 2, 2024
StartEst.
Jan 2024
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Jan 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06186544
Lead sponsor
Cardiff and Vale University Health Board
Collaborators
The European Vascular Research Collaborative (EVRC)
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Jan 2024 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jan 2, 2024

Study contacts

Maram Darwish, MD
Contact
maram.darwish@wales.nhs.uk
+447841582039
Rachel Norman
Contact
rachel.norman2@wales.nhs.uk
+442921846126
Lewis Meecham, FRCS
principal investigator · Cardiff and Vale University Health Board

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion